Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma | 507789

Market Closed
₹209.27
₹1.16 (-0.55%)
As on 23/11/26, 12:42 AM
Market Cap1,390.02 CR
Current Price₹209.27
High / Low₹264.5 / 155
PE Ratio---
Book Value₹---
Dividend Yield---
ROCE---
ROE16.69%
Face Value₹2.00
Current Vol.18,367
Average Vol.---
ISININE048B01035
PB Ratio---
Debt to Equity---
Net Profit Margin---
Operating Margin---

JAGSNPHARM - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹210.42₹208.2
₹209.27
Previous CloseToday's Open
₹155₹264.5
₹209.27
52W Low52W High
₹208.2Today's Open
₹210.42Previous Close
18,367Volume
₹15552W Low
₹264.552W High

Ratios

📊

Consolidated data not available

Please try selecting a different data type

About Company

  • Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana
  • The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs
  • Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd
  • The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India
  • It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product
  • In 1994, the company has also promoted Aresco Financial Services, a new financial company
  • The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment
  • It's R&D activities are geared towards development of new product technologies which can be commercialised in future
  • It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia
  • In the fiscal 2001, the company's sales grew by 15% to Rs 136

Ethics: Jagsonpal Pharmaceuticals Ltd is flagged for

worldwide image

Adequate

The company demonstrates adequate ESG practices with room for improvement.

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI38.28
SMA 20217.04
SMA 50223.70
SMA 100228.21
SMA 200211.14
SMA 10213.84
MACD_12_26_Days-3.74
EMA10Day213.00
EMA20Day215.92
EMA50Day221.29
MACD_12_26_9_Days-0.44
EMA100Day221.99
EMA200Day218.62

Pivot Points

Volume Analysis

Delivery
Total Volume
Growth Rate
📊

No Information Available

Growth Rate information is not available at this time.

All figures in ₹ Crores

📊

No Information Available

No profit & lossdata available

Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

DealDateTypeQuantityPriceTraded %
INFINITY PORTFOLIO HOLDINGS13 Sept ‘24Purchase22,00,000₹400851.62%
INFINITY HOLDINGS13 Sept ‘24Sell22,00,000₹400851.62%

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
18 Sept 2026
AGM
AGM
19 Aug 2026
04 Sept 2026
Final Dividend (₹4)
The Board recommended a dividend of Rs. 4/- (200%) per equity share having face value of Rs. 2 for the financial year ended March 31, 2026
27 Apr 2026
08 May 2026
Buyback
Tender Offer - Max Price: ₹250, Amount: ₹40Cr
12 Mar 2026
24 Sept 2025
AGM
AGM
26 Jul 2025
12 Sept 2025
Final Dividend (₹2.5)
The Board recommended a dividend of Rs. 2.5/- (125%) per equity share having face value of Rs. 2 for the financial year ended March 31, 2025. The 46th Annual General Meeting of the company will be held on September 24, 2025. The company has fixed September 12, 2025 as a Record Date for determining eligibility of shareholders for payment of Dividend. (As Per BSE Announcement Dated on :26.07.2025)
06 May 2025
08 Jan 2025
Stock Split (1:2.5)
Face Value Change from 5 To 2
23 Oct 2024
18 Sept 2024
AGM
AGM
07 Aug 2024
06 Sept 2024
Final Dividend (₹5)
Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2024. In this regard, kindly find enclosed the following: 1.The Board recommended a dividend of Rs. 5/- (100%) per equity share for the financial year ended March 31, 2024.
20 May 2024
31 Aug 2023
AGM
AGM
05 Aug 2023
21 Aug 2023
Final Dividend (₹5)
The Board of Directors at their meeting held today have recommended dividend of Rs. 5/- per equity share of face value of Rs. 5/- for the financial year ended March 31, 2023. The dividend shall be payable after it is approved by the shareholders at the 44th Annual General Meeting of the Company. Pursuant to Regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has fixed Monday, August 21, 2023, as the Record Date for determining the entitlement of Members to dividend for the financial year ended March 31, 2023. (As Per BSE Announcement Dated on 08.08.2023)
23 May 2023

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
208
0
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 141 Results

Frequently Asked Questions

What is Share Price of Jagsonpal Pharmaceuticals Ltd?

The current share price of Jagsonpal Pharmaceuticals Ltd (Jagsonpal Pharma) is ₹209.27. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd has a 52-week high of ₹264.50 and a 52-week low of ₹155.00. This range shows the stock's price volatility over the past year.

What is the ROE of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd has a Return on Equity (ROE) of 16.69%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2